Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with moderately active Crohn's disease or ulcerative colitis are defined by fulfilling all the following five criteria:
- Well-characterized Crohn's disease or ulcerative colitis (physician assessment) i. Fulfilling standard clinical, endoscopic, radiologic, and histological criteria
- A minimum of one-year disease duration from the time of diagnosis of Crohn's disease or ulcerative colitis to inclusion into the trial
- Any of the following pharmacological treatments in a period of three months prior to inclusion:
i. Usage of 5-Aminosalicylic acid (5-ASA) ii. Usage of corticosteroids iii. Immunomodulators usage: Azathioprine (AZA), 6-mercaptopurine (6-MP), Methotrexate (MTX) iv. Biologics usage: Anti-TNFα (Infliximab, Adalimumab, Golimumab), Ustekinumab or Anti-integrin (Vedolizumab)
- Disease activity defined by clinical disease score:
i. Harvey Bradshaw Index (HBI) 27 > 5 ii. Simple Clinical Colitis Activity Index (SCCAI) 29 > 5
- Marker for gastrointestinal inflammation:
i. Fecal calprotectin (FC) > 200 mg/g
Exclusion criteria
- 1. A language barrier that prohibits the exercise instructors/supervisors to give sufficient or safe instructions during the intervention or at the general health lesson.
- Known heart condition that prevents them to actively participate safely in the exercise intervention.
- Known pregnancy or planned pregnancy. 4. Disabling musculoskeletal injuries that prevent them to actively participate in the exercise intervention.
- Severe disease activity manifested clinically and with the need for urgent change in treatment evaluated by the responsible physician.
